Pulmonary complications associated with combination chemotherapy programs containing bleomycin.
D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D003907:Dexamethasone / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects; D008171:Lung Diseases / Q000139:chemically induced*; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D012128:Respiratory Distress Syndrome / Q000139:chemically induced; D013736:Testicular Neoplasms / Q000188:drug therapy; D014747:Vinblastine / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects
D001761:Bleomycin; D014750:Vincristine; D014747:Vinblastine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D002955:Leucovorin; D008727:Methotrexate